NasdaqGS:IMVTBiotechs
Immunovant (IMVT) Stock Could Be 14.1% Undervalued After Loss And Trial Updates
Immunovant (IMVT) is back in focus after reporting a wider than expected quarterly loss tied to IMVT-1402 development and batoclimab discontinuation costs, along with updates on its Graves' Disease and CIDP programs.
See our latest analysis for Immunovant.
Against that backdrop, Immunovant’s share price has risen strongly, with a 90 day share price return of 53.79% and a 1 year total shareholder return of 123.67%, signaling firm momentum as investors weigh its IMVT-1402 and CIDP updates.
If...